Interim Results for the six months
ended 31 October 2013
Parsortix development completed and
CE Mark awarded
Andrew Newlan...
Legal disclaimer
The information and opinions contained in this presentation are provided as at the date hereof and are su...
Highlights
Completed the key development phase for the Parsortix system for
capturing circulating tumour cells (CTCs)
Bala...
Financial Results for the six months ended 31 October 2013
H1 2014

H1 2013

£’000

£’000

Revenue

414

467

Investments ...
Parsortix PR1 Machine successfully developed

© ANGLE plc 2014

Page 5
Parsortix PR1 System set for automated harvesting

© ANGLE plc 2014

Page 6
GEN3 cassette: captured HT-29 colorectal cancer cells

CK20 –green
CD45 – red
Nuclear stain - blue
HT29: CK20+ CD45WBC: CK...
Key applications of Parsortix
Presence

− Microscope slide capture device enables the morphological examination of
capture...
Research partners
University of Surrey Oncology Department
Colorectal cancer patient validation
High CTC capture rate
Pars...
Sales platform
Sales priority to establish Parsortix in clinical practice

− working with cancer research centres to ident...
Cambridge Parsortix laboratory
Partnership with Medical Research Council’s Cancer Unit at the
University of Cambridge to e...
Next Generation Sequencing
Third Scientific Adviser appointed
Dr Harold Swerdlow leading expert in next-generation sequenc...
Objectives for current financial year
Strengthen balance sheet with sale of Geomerics - achieved
Place Parsortix system wi...
Contact details

Andrew Newland
ANGLE plc
3 Frederick Sanger Road
The Surrey Research Park
Guildford GU2 7YD
United Kingdo...
Upcoming SlideShare
Loading in …5
×

ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013

345 views

Published on

Published in: Health & Medicine, Technology
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
345
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013

  1. 1. Interim Results for the six months ended 31 October 2013 Parsortix development completed and CE Mark awarded Andrew Newland and Ian Griffiths 30 January 2014
  2. 2. Legal disclaimer The information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment (without notice), verification and completeness. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published in whole or in part for any purpose. This document is being provided to recipients on the basis that they keep confidential any information contained herein or otherwise made available, whether orally or in writing, in connection with the Company. Neither this document or any part of this document nor any copy of it may be sent to or taken into the United States of America, Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland, nor may it be distributed to, directly or indirectly, to any US person (within the meaning of regulation S promulgated under the United States Securities Act of 1933, (as amended) (the “US Securities Act”)). This document does not constitute an offer to buy or to subscribe for, or the solicitation of an offer to buy or to subscribe for securities in the Company. To the extent this document is received or used in jurisdictions outside the UK, any such recipient or user should inform themselves about and observe any applicable legal requirements. Neither this document nor any part of this document should be copied or distributed by recipients and, in particular, should not be distributed by any means, including electronic transmission, to persons with addresses in the United States of America (or any of its territories or possessions) Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland or to any citizens, residents or nationals thereof, or to any corporation, partnership or other entity created or organised under the laws thereof or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Any such distribution could result in violation of the laws of such countries. This document does not constitute or form any part of any offer or invitation or other solicitation or recommendation to purchase any securities in the Company and does not constitute or form part of a prospectus. No reliance may be placed for any purpose whatsoever on the information, representation or opinions. This document should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters. Neither the Company nor any other person makes any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this document, nor does the Company accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith. Forward-Looking Statements This presentation and the associated commentary contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve significant risks and uncertainties. These statements are based on information currently available to the Company; and actual results could differ materially from those stated or implied, due to risks and uncertainties associated with its business. Forward-looking statements include statements regarding expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “potential”, “target”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “should”, “will”, and “would” or similar words. ANGLE assumes no obligation to update the information included in this presentation, whether as a result of new information, future events or otherwise. © ANGLE plc 2014 Page 2
  3. 3. Highlights Completed the key development phase for the Parsortix system for capturing circulating tumour cells (CTCs) Balance sheet and medtech focus strengthened by sale of Geomerics to ARM Holdings for up to £6.2m - £5.5m already received CE Mark awarded for clinical use in Europe Parsortix system well received by research partners, University of Surrey Oncology Group and Cancer Research UK’s Paterson Institute for Cancer Research Now being evaluated by key opinion leaders in the fields of cancer diagnosis and treatment ANGLE now focused on securing US regulatory authorisation and building the platform for widespread market adoption for the treatment of cancer patients © ANGLE plc 2014 Page 3
  4. 4. Financial Results for the six months ended 31 October 2013 H1 2014 H1 2013 £’000 £’000 Revenue 414 467 Investments portfolio gain 404 286 818 753 (1,374) (1,126) 80 14 (476) (359) 31Oct13 30Apr13 4,839 3,961 Trade and other receivables 530 454 Inventories 15 62 Cash 358 1,828 Property, plant and equipment 198 138 Intangible assets 1,099 1,080 Total assets 7,039 7,523 Statement of Comprehensive Income Operating costs Other income Loss before tax Statement of Financial Position Investments Comments Increased investment principally in Parsortix of £1.1m up from £0.8m • • Operating costs £0.8m Capitalised expenditure £0.3m Geomerics non-core investment £4.8m • • • Sold after period end Up to £6.2m cash £5.5m received Value of investments increased by £0.9m © ANGLE plc 2014 Page 4
  5. 5. Parsortix PR1 Machine successfully developed © ANGLE plc 2014 Page 5
  6. 6. Parsortix PR1 System set for automated harvesting © ANGLE plc 2014 Page 6
  7. 7. GEN3 cassette: captured HT-29 colorectal cancer cells CK20 –green CD45 – red Nuclear stain - blue HT29: CK20+ CD45WBC: CK20- CD45+ Spiked whole blood Source: University of Surrey Oncology Department © ANGLE plc 2014 Page 7
  8. 8. Key applications of Parsortix Presence − Microscope slide capture device enables the morphological examination of captured cells with clear visibility of cell structure − Step separation of 20µm allows easy visual sizing of cells − Automated cell identification possible in situ within the cassette with a choice of up to 7 reagents e.g. CK18+, DAPI+ and CD45- Counting − Microscope slide format enables the user to view and count captured cells − Indication of disease status and progression Harvesting − Automated recovery of intact, undamaged, viable cells allows DNA analysis − High level of cell purity © ANGLE plc 2014 Page 8
  9. 9. Research partners University of Surrey Oncology Department Colorectal cancer patient validation High CTC capture rate Parsortix system demonstrated twice the sensitivity of currently accepted clinical practice for CTC capture Cancer Research UK’s Paterson Institute for Cancer Research Positive evaluation. Key advantages identified: − Epitope independent (does not use antibody capture) − “Plug and play” − Operationally versatile − Biomarker compatible (harvested cells can be analysed) Parsortix included in Paterson’s ongoing efforts to deliver personalised medicine © ANGLE plc 2014 Page 9
  10. 10. Sales platform Sales priority to establish Parsortix in clinical practice − working with cancer research centres to identify clinical applications − securing positive clinical data demonstrating medical utility − key opinion leader support 21 Parsortix PR1 systems deployed – 12 with key cancer groups − 5 with research partners, Cancer Research UK’s Paterson Institute for Cancer Research and the University of Surrey Oncology Group − 3 leading cancer research centres in London, Cambridge and Germany − 3 leading hospitals in London and Oxford − 1 with a diagnostic company Priority deployment of machines with key cancer groups Beginning deployment of systems in support of research sales Expect revenues to take time to develop and be modest initially As each clinical application established expect sustained revenue growth for that application © ANGLE plc 2014 Page 10
  11. 11. Cambridge Parsortix laboratory Partnership with Medical Research Council’s Cancer Unit at the University of Cambridge to establish a Cambridge Parsortix laboratory MRC Cancer Unit is a key opinion leader MRC Cancer Unit research team, and the wider scientific community at the University of Cambridge and Addenbrooke’s hospital, access to the Parsortix system Important recognition of the Parsortix system that the MRC Cancer Unit has decided to invest in establishing a stand-alone Parsortix laboratory within its facility Core areas of investigation − Bowel cancer including colorectal, pancreatic and oesophageal cancers − Detection of cancer − New drug compounds − Gene mutation analysis and next-generation sequencing (NGS) © ANGLE plc 2014 Page 11
  12. 12. Next Generation Sequencing Third Scientific Adviser appointed Dr Harold Swerdlow leading expert in next-generation sequencing (NGS) Head of Research and Development for Wellcome Trust Sanger Institute Invented core technology relating to NGS and commercialised this at Solexa Ltd Solexa was acquired by Illumina for US$600 million Directs all next-generation DNA sequencing at Sanger NGS premier technique in genetic and genomic analysis, fundamental to personalised cancer treatment Aligning Parsortix with NGS key commercial objective © ANGLE plc 2014 Page 12
  13. 13. Objectives for current financial year Strengthen balance sheet with sale of Geomerics - achieved Place Parsortix system with key opinion leaders – in progress 3rd party validation of the Parsortix system - achieved Select a manufacturing partner and establish quality control systems achieved Plan for regulatory authorisation for the product to be used in the clinical market - achieved CE Mark authorisation for clinical sales in the Europe - achieved Application to the FDA for authorisation for clinical sales in the United States in Q1 2014 Market entry plan for Parsortix © ANGLE plc 2014 Page 13
  14. 14. Contact details Andrew Newland ANGLE plc 3 Frederick Sanger Road The Surrey Research Park Guildford GU2 7YD United Kingdom Tel: +44 1483 685830 Fax: +44 1483 685836 Email: andrew.newland@ANGLEplc.com Website: www.ANGLEplc.com © ANGLE plc 2014 Page 14

×